Identification and characterization of cytochrome P4502D6*56B (CYP2D6*56B), a novel allele associated with the poor metabolizer phenotype.

被引：0
|
作者：
Gaedigk, A. [1 ]
Eklund, J. D. [1 ]
Pearce, R. E. [1 ]
Leeder, J. S. [1 ]
Alander, S. W. [1 ]
Bradford, L. D. [1 ]
Kennedy, M. J. [1 ]
机构：
[1] Univ Louisville, Childrens Mercy Hosp, Morehouse Sch Med, Kansas City, MO USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2007年 / 81卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S85 / S85
页数：1
相关论文
共 50 条
  • [31] Therapeutic Drug Monitoring of Psychotropics as a Diagnostic Tool for CYP2D6 Poor Metabolizer Phenotype
    Ganesh, Soraya, V
    Beunk, Lianne
    Nikolik, Bojan
    van der Weide, Jan
    Bet, Pierre M.
    THERAPEUTIC DRUG MONITORING, 2021, 43 (05) : 672 - 680
  • [32] Correlation between cytochrome P-450CYP2D6 CYP2D6) genotype and phenotype
    Chen, SQ
    Wedlund, PJ
    ACTA PHARMACOLOGICA SINICA, 1999, 20 (07): : 585 - 588
  • [33] Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test
    Laine, K
    Tybring, G
    Härtter, S
    Andersson, K
    Svensson, JO
    Widén, J
    Bertilsson, L
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 70 (04) : 327 - 335
  • [34] FREQUENCY OF A SPECIFIC CYTOCHROME P4502D6B (CYP2D6B) MUTANT ALLELE IN CLINICALLY DIFFERENTIATED GROUPS OF PATIENTS WITH PARKINSON DISEASE
    AKHMEDOVA, SN
    PUSHNOVA, EA
    YAKIMOVSKY, AF
    AVTONOMOV, VV
    SCHWARTZ, EI
    BIOCHEMICAL AND MOLECULAR MEDICINE, 1995, 54 (02) : 88 - 90
  • [35] Heterozygosity for the most common poor metabolizer allele (CYP2D6*4) was not associated with increased susceptibility to ankylosing spondylitis (AS)
    Marzouk, K.
    Pope, A.
    Hamilton, S.
    Rahman, P.
    Peddle, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 405 - 405
  • [36] Functional Characterization of Cytochrome P450 2D6 (CYP2D6) Allelic Variant CYP2D6*10
    Dong, A. N.
    Ong, C. E.
    Pan, Y.
    Palanisamy, U. D.
    Ismail, R.
    PUBLIC HEALTH GENOMICS, 2015, 18 : 49 - 49
  • [37] IDENTIFICATION OF A NEW VARIANT CYP2D6 ALLELE WITH A SINGLE-BASE DELETION IN EXON-3 AND ITS ASSOCIATION WITH THE POOR METABOLIZER PHENOTYPE
    SAXENA, R
    SHAW, GL
    RELLING, MV
    FRAME, JN
    MOIR, DT
    EVANS, WE
    CAPORASO, N
    WEIFFENBACH, B
    HUMAN MOLECULAR GENETICS, 1994, 3 (06) : 923 - 926
  • [38] The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes - Independent commentary
    Brosen, K
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 58 (07) : S749 - S750
  • [39] Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype
    Martinez de Duenas, Eduardo
    Ochoa Aranda, Enrique
    Blancas Lopez-Barajas, Isabel
    Ferrer Magdalena, Teresa
    Bandres Moya, Fernando
    Chicharro Garcia, Luis Miguel
    Gomez Capilla, Jose A.
    Zafra Ceres, Mercedes
    de Haro, Tomas
    Romero Llorens, Regina
    Ferrer Albiach, Carlos
    Ferriols Lisart, Rafael
    Chover Lara, Dolores
    Lopez Rodriguez, Angela
    Munarriz Ferrandis, Javier
    Olmos Anton, Santiago
    BREAST, 2014, 23 (04): : 400 - 406
  • [40] CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment
    Almoguera, Berta
    Riveiro-Alvarez, Rosa
    Lopez-Castroman, Jorge
    Dorado, Pedro
    Vaquero-Lorenzo, Concepcion
    Fernandez-Piqueras, Jose
    LLerena, Adrian
    Abad-Santos, Francisco
    Baca-Garcia, Enrique
    Dal-Re, Rafael
    Ayuso, Carmen
    PHARMACOGENETICS AND GENOMICS, 2013, 23 (11): : 627 - 630
12345